DOP46 Tofacitinib for hospitalized acute severe Ulcerative Colitis – the TRIUMPH study
Neeraj Narula(McMaster University), John K. Marshall(McMaster University), Brian Bressler(University of British Columbia), Farhad Peerani(University of Alberta), Jeff Castelli(Université Paris-Saclay), A. B. Arun(McMaster University), M Schmit(Child and Family Research Institute), Talat Bessissow(Montreal General Hospital)
Cited by 8
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
|Journal of Crohn s and Colitis|2019|1.4k
ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment
|Journal of Crohn s and Colitis|2019|1.1k
Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management
|Clinical and Translational Gastroenterology|2016|724